Skip to main content

Table 3 Correlation of ALK FISH with clinicopathologic parameters in breast cancer

From: ALK alteration is a frequent event in aggressive breast cancers

  Total Amplified Non-amplified P value
  N % N % N %
Total number of cases 980   130 13.3 850 86.7  
Age groups        
 <50 666 68.0 85 12.8 581 87.2 0.5018
 ≥50 314 32.0 45 14.3 269 85.7  
Lymph nodes        
 N0 305 33.1 38 12.5 267 87.5 0.2010
 N1 295 32.1 47 15.9 248 84.1  
 N2 192 20.8 25 13.0 167 87.0  
 N3 128 13.9 11 8.6 117 91.4  
Metastasis        
 M0 789 89.7 111 14.1 678 85.9 0.5986
 M1 91 10.3 11 12.1 80 87.9  
Tumor stage        
 I 77 9.0 9 11.7 68 88.3 0.7588
 II 374 43.8 57 15.2 317 84.8  
 III 311 36.5 42 13.5 269 86.5  
 IV 91 10.7 11 12.1 80 87.9  
Histologic grade        
 Well differentiated 74 7.6 7 9.5 67 90.5 0.3393
 Moderately differentiated 498 51.4 62 12.4 436 87.6  
 Poorly differentiated 397 41.0 59 14.9 338 85.1  
Histology        
 Infiltrating ductal 896 94.0 124 13.8 772 86.2 0.0194
 Infiltrating lobular 44 4.6 1 2.3 43 97.7  
 Mucinous 13 1.4 3 23.1 10 76.9  
Recurrence        
 Yes 257 29.7 42 16.3 215 83.7 0.1569
 No 308 70.3 77 12.7 531 87.3  
ER*        
 Negative 332 33.9 48 14.5 284 85.5 0.4388
 Positive 647 66.1 82 12.6 565 87.4  
PR*        
 Negative 408 41.9 58 14.2 350 75.8 0.4010
 Positive 566 58.1 70 12.4 496 87.6  
Triple-negative*        
 Yes 141 14.5 16 11.3 125 88.7 0.4848
 No 832 85.5 112 13.5 720 86.5  
HER2 FISH*        
 Amplified 282 29.5 48 17.0 234 83.0 0.0418
 Normal/gain 675 70.5 81 12.0 594 88.0  
ALK IHC*        
 Present 345 36.4 61 17.7 284 82.3 0.0031
 Absent 602 63.6 65 10.8 537 89.2  
Ki-67 IHC        
 High 825 86.3 117 14.2 708 85.8 0.0569
 Low 131 13.7 11 8.4 120 91.6  
p-AKT        
 Positive 210 22.4 31 14.8 179 85.2 0.4232
 Negative 729 77.6 92 12.6 637 87.4  
Molecular subtype        
 HR+Her2- 461 47.2 58 12.6 403 87.4 0.6418
 HR+Her2+ 238 24.4 33 13.9 205 86.1  
 TNBC 141 14.4 16 11.4 125 88.6  
 HR-Her2+ 139 13.9 22 16.2 114 83.8  
Survival        
 OS 5 years     77.3   80.3 0.3303
  1. ALK anaplastic lymphoma kinase, FISH fluorescence in situ hybridization, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, HR hormone receptor, TNBC triple-negative breast cancer, OS overall survival
  2. *Data was not available (NA) for some cases: Age (NA = 27), Lymph nodes (NA = 72), Metastasis (NA = 100), Stage (NA = 144), Grade (NA = 53), Histology (NA = 27), ER (NA = 1), PR (NA = 6),Triple-negative (NA = 7), HER-2 FISH (NA = 23), ALK FISH (NA = 33), Ki-67 (NA = 24)